Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anastrozole for hormone-sensitive recurrent or metastatic gynecological cancers
ACTRN12610000796088Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of anastrozole in gynecological cancer, ovarian cancer, primary peritoneal cancer (PPC) and 6 more, sponsored by University of Sydney. Primary endpoint: Overall response to treatment. Started Jan 2012; status: completed.
02
Drugs
anastrozole
03
Conditions
gynecological cancerovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)endometrial cancer (EC)
Beyond the preview
Go deeper on ACTRN12610000796088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000796088.